Own Medibank (ASX:MPL) shares? Now you own a piece of this tech start-up

What new investment did Medibank announce today?

Key points
  • Medibank has invested $10 million in virtual health  
  • The private health insurer's share price is making little impact today
  • Medibank shareholders have seen a 10% boost in returns in the past 12 months 

The Medibank Private Ltd (ASX: MPL) share price is making little headway today. It is currently flat at $3.21 having earlier jumped to $3.25.

For comparison, the S&P/ASX 200 Index (ASX: XJO) is up 1.15% at the time of writing.

However, there is an interesting piece of news out of Medibank today. The private health insurance company has announced a new multi-million investment in a health technology company.

Let's take a look.

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.

Image source: Getty Images

Virtual health investment

Medibank has invested $10 million in the health technology company Medinet. The aim is to support the increasing role of virtual health in Australia.

Medinet is a digital platform providing patients with access to doctors online via video, audio, and chat. The platform was launched in 2019 and is being used in some GP clinics in Australia. The app is within the top five healthcare apps downloaded in the country.

Commenting on the investment, Medibank Group Executive – CEO Health Services Dr Andrew Wilson said:

People are looking for the same level of choice and convenience in their healthcare that they get in other parts of their lives. The COVID pandemic has accelerated the use and acceptance of technology-enabled healthcare, with recent research showing that 70% of Australians are willing to use virtual healthcare services.

Medinet's platform supports this by giving patients the ability to make an appointment and connect with a GP virtually, to access scripts and referrals generated during the consult, and to have their medication delivered straight to their home.

Credit Suisse has recently rated the Medibank share price as a "buy" with a $3.50 price target. Medibank increased operating profit by 12.3% in the first half of FY22, while net profit after tax (NPAT) descended 2.7%. Policyholder numbers climbed 1.5% in the half while jumping 3.3% in 12 months.

On March 24, Medibank will pay a dividend of 6.1 cents per share.

Medibank share price recap

The Medibank share price has climbed 10% in the past 12 months, but it has fallen 4% year to date.

For perspective, the benchmark ASX 200 index has leapt 7% in the past 52 weeks.

In the past month, Medibank shares are in the red by 0.3% but they have jumped by 5% in the past week.

Medibank has a market capitalisation of about $8.9 billion based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Senior man looking at his laptop and pondering something.
Healthcare Shares

Could Mesoblast shares rise over 100% in 12 months?

Bell Potter has given its view on this stock.

Read more »

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »